[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340261-105":59,"doc-detail-340261-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-t-therapy-for-gastrointestinal-cancers-current-status-challenges-and-future-directions","CAR-T therapy for gastrointestinal cancers - current status, challenges, and future directions","","Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic strategy with proven efficacy in hematological malignancies, yet its translation to solid tumors, especially gastrointestinal cancers, remains limited by key obstacles. These include selecting appropriate target antigens, overcoming the complex tumor microenvironment, and managing safety and toxicity concerns. This review summarizes current progress across esophageal, gastric, colorectal, pancreatic, and liver cancers, addresses major limitations, and outlines future directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-therapy-for-gastrointestinal-cancers-current-status-challenges-and-future-directions/340261/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-therapy-for-gastrointestinal-cancers-current-status-challenges-and-future-directions/340261.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major challenges limit CAR-T therapy in gastrointestinal cancers?","Question",{"text":112,"@type":113},"Challenges include selecting suitable target antigens, addressing the immunosuppressive tumor microenvironment, and mitigating safety/toxicity concerns, along with limited standardized protocols and regulations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which gastrointestinal cancers are covered in the review?",{"text":117,"@type":113},"The review covers multiple gastrointestinal cancer types, including esophageal, gastric, colorectal, pancreatic, and liver cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What future directions does the review highlight?",{"text":121,"@type":113},"It highlights innovative strategies such as novel target antigens, multispecific and armored CAR-T cells, universal CAR-T approaches, and work on biomarkers and predictors, alongside combination and design optimization strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340261,1790167672,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Brazilian Journal of Medical and Biological Research (2024) 57: e13640, [https://doi.org/10.1590/1414-431X2024e13640](https://doi.org/10.1590/1414-431X2024e13640)  \nISSN 1414-431X Review  \n1/12  \nCAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions  \nWeidong Li 1 00 , Yueming Huang 1 00 , Xinhao Zhou 1 00 , Bohao Cheng 1 00 , Haitao Wang 1 00 , and  \nYao Wang 1 00  1Department of Gastrointestinal Surgery, Zhongshan City People’s Hospital, Zhongshan, Guangdong, China  \nAbstract  \nChimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapeutic strategy that has shown efﬁcacy in hematological malignancies. However, its application in solid tumors, particularly gastrointestinal cancers, faces signiﬁcant challenges. These include the selection of target antigens, the complexity of the tumor microenvironment, and safety and toxicity concerns. This review provides a current overview of CAR-T therapy in various gastrointestinal cancers, such as esophageal, gastric, colorectal, pancreatic, and liver cancers. It discusses the limitations and future directions of CAR-T therapy in this context. This review highlights innovative strategies, including novel target antigens, multispeciﬁc CAR-T cells, armored CAR-T cells, and the development of universal CAR-T cells. These insights aim to inform ongoing research and foster advancements in CAR-T therapy for gastrointestinal cancers.  \nKey words: CAR-T therapy; Gastrointestinal cancers; Target antigens  \nIntroduction  \nGastrointestinal cancers are malignant tumors that arise in the organs of the digestive system, such as the esophagus, stomach, liver, pancreas, gallbladder, small intestine, and colorectum. Some of the risk factors for gastrointestinal cancers include chronic inﬂammation, infection, obesity, smoking, alcohol consumption, dietary habits, genetic mutations, and family history. Gastrointestinal cancers are among the most common and deadly cancers worldwide, accounting for about 25% of all cancer cases and 30% of all cancer deaths (1,2) . Despite the advances in surgery, chemotherapy, radiotherapy, and targeted therapy, the prognosis of patients with gastrointestinal cancers remains poor, especially for those with advanced or metastatic disease (3) . Therefore, there is an urgent need for novel and effective therapies that can improve the survival and quality of life of these patients. One of the most promising therapies for cancer is chimeric antigen receptor (CAR) T-cell therapy, which harnesses the power of the immune system to ﬁght cancer cells. In this approach, patient T cells are genetically modiﬁed to express a CAR that converts T cells of any speciﬁcity into tumor-speciﬁc T cells. These cells can be expanded signiﬁcantly and then readministered to the patient, so that they target and eliminate cancer cells, even in cases of extensive metastatic disease (4,5) . CAR-T therapy has shown remarkable efﬁcacy in hematological malignancies,  \nleading to the approval of four CAR-T products by the Food and Drug Administration (FDA) for B cell malignancies (6) .  \nHowever, the application of CAR-T therapy to solid tumors, especially gastrointestinal cancers, remains challenging due to several factors, such as the identiﬁcation of suitable target antigens, the immunosuppressive tumor microenvironment, the potential toxicity and cost of CAR-T therapy, and the lack of standardized protocols and regulations (7) . Despite these challenges, several clinical trials have explored the feasibility and safety of CAR-T therapy in gastrointestinal cancers, targeting antigens such as: CEA, HER2, MUC1, GPC3, and CLDN18 .2 (8) . Some of these trials have reported partial or complete responses in patients with advanced or refractory disease. However, the overall efﬁcacy of CAR-T therapy in gastrointestinal cancers remains modest and variable (9) .  \nThis review aims to provide an update on the advances and challenges of CAR-T therapy in gast","cbCainZqhrihumdd","https://ap.wps.com/l/cbCainZqhrihumdd","pdf",308285,12,"English","# Abstract\n# Introduction\n## Background and clinical need\n## CAR-T therapy rationale and challenges\n# Scope and structure of the review\n## Study inclusion and exclusion criteria\n## Clinical and preclinical evidence sources","[{\"question\":\"What major challenges limit CAR-T therapy in gastrointestinal cancers?\",\"answer\":\"Challenges include selecting suitable target antigens, addressing the immunosuppressive tumor microenvironment, and mitigating safety/toxicity concerns, along with limited standardized protocols and regulations.\"},{\"question\":\"Which gastrointestinal cancers are covered in the review?\",\"answer\":\"The review covers multiple gastrointestinal cancer types, including esophageal, gastric, colorectal, pancreatic, and liver cancers.\"},{\"question\":\"What future directions does the review highlight?\",\"answer\":\"It highlights innovative strategies such as novel target antigens, multispecific and armored CAR-T cells, universal CAR-T approaches, and work on biomarkers and predictors, alongside combination and design optimization strategies.\"}]","CAR-T therapy for gastrointestinal cancers - current status, challenges, and future directions | PDF",1790035351,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b3449e09914433bbffc7f09ed9805be.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/655eab78ade985709a43f8e905ed105e.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/390e32cd1928262a337a3960a6faf44f.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a26f93fcc78fcc3fbab4e4ece13f3407.webp",980,1265]